– ABOUT

Omico’s PrOSPeCT Program

Omico is transforming cancer care in Australia by accelerating access to precision oncology. As a national, independent, not-for-profit organisation, Omico brings together Australia’s leading cancer institutes, researchers, clinicians, industry partners, and government to revolutionise how we fight cancer. By harnessing a nationwide network of expertise and resources, Omico strives to improve outcomes for cancer patients across the country, enabling faster access to next-generation treatments and preventive strategies.

A cornerstone of Omico’s efforts is the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), the largest cancer genomics initiative in Australia. Over 27 months, PrOSPeCT’s Cancer Screening Program (CaSP) will offer comprehensive genomic profiling to 23,000 Australians with advanced or poor-prognosis cancers, connecting them to biomarker-led clinical trials for innovative treatments. This initiative is poised to save an estimated $135 million in healthcare costs and attract $525 million in new investment for locally-based clinical trials, establishing Australia as a global hub for precision oncology research and innovation.

Omico and its partners, including Bioplatforms, are helping to fast-track the development of targeted cancer therapies, improve patient outcomes, and create over 650 new jobs in clinical trials, diagnostics, and genomics research.